Pfizer And Taisho Reach Deal for Schizophrenia Candidate
This article was originally published in The Pink Sheet Daily
Pfizer joins Merck and AstraZeneca in pursuing metabotropic glutamate receptor agonist candidates.
You may also be interested in...
Firms collaborate to develop a metabotropic glutamate receptor 5 target, a possible pathway for treatment of schizophrenia.
NPS says it will use the money to fund further development of late-stage candidates Preos and Gattex.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?